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Abstract. The specific CB2 cannabinoid receptor agonist JWH-133 induced cognitive improvement in double APP/PS1 trans-
genic mice, a genetic model of Alzheimer’s disease. This effect was more pronounced when administered at the pre-symptomatic
rather than the early symptomatic stage. The cognitive improvement was associated with decreased microglial reactivity and
reduced expression of pro-inflammatory cytokines IL-1, IL-6, TNF, and IFN. In addition, JWH-133 reduced the expression
of active p38 and SAPK/JNK, increased the expression of inactive GSK3, and lowered tau hyperphosphorylation at Thr181
in the vicinity of amyloid- plaques. Moreover, JWH-133 produced a decrease in the expression of hydroxynonenal adducts,
and enhanced the expression of SOD1 and SOD2 around plaques. In contrast, the chronic treatment with JWH-133 failed to
modify the amyloid- production or deposition in cortex and hippocampus. In conclusion, the present study lends support
to the idea that stimulation of CB2 receptors ameliorates several altered parameters in Alzheimer’s disease such as impaired
memory and learning, neuroinflammation, oxidative stress damage and oxidative stress responses, selected tau kinases, and tau
hyperphosphorylation around plaques.
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INTRODUCTION
Alzheimer’s disease (AD) is considered to be the
result of a multifactorial neurodegenerative process in
which, in addition to amyloid- (A) deposition and
neuronal tau hyperphosphorylation, numerous path-
waysarealtered, leadingtoimpairedenergyprocessing,
oxidative stress damage, and inflammation [1, 2].
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Bellvitge, C/Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat,
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Cannabinoid compounds have emerged as potential
therapeutic agents against AD because of their known
multifaceted neuroprotective properties [3, 4]. The
endocannabinoid system is composed of at least two
well-characterized cannabinoid Gi/o-coupled recep-
tors, CB1 and CB2, their endogenous ligands, and the
enzymes related to their synthesis and degradation [5].
The CB1 receptor is widely expressed within the cen-
tral nervous system, in both neurons and glial cells,
where it regulates important brain functions [6, 7].
Recent studies have shown that low non-psychotropic
doses of specific CB1 agonists exhibited potential ther-
apeutic properties in AD [8]. However, among the
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extensive range of natural and synthetic cannabinoids,
major attention in AD has been paid to CB2 receptor
specific agonists because of their lack of psychoac-
tive properties. CB2 receptors are mainly expressed
in the immune system, including microglial cells [9,
10], but relatively lower expression of CB2 recep-
tors in neurons has been proposed as well [11–14].
In AD postmortem brains, CB2 receptors have been
reported to be overexpressed in A plaques-associated
microglia, suggesting these receptors as potential ther-
apeutic targets [15]. The activity of CB2 receptors
is implicated in the reduction of pro-inflammatory
molecules in response to harmful stimuli [16] and in
the control of neural survival [17]. In line with these
observations, activation of CB2 receptors had the ben-
eficial effects of inducing cognitive improvement and
reducing neuroinflammatory response in two different
in vivo models of AD [18–21]. Moreover, stimula-
tion of CB2 receptors produced A removal by human
macrophages, at least in the context of very specific
settings [22], and lowered the A levels in transgenic
APP2576 mice after a prolonged oral administration
[20]. Certain cannabinoids were also capable of reduc-
ing tau phosphorylation via CB2 receptors in PC12
cells and in cultured neurons [23, 24]. However, other
effects of CB2 receptor agonists as therapeutic agents
in AD need further study. Thus, the present study was
aimed to evaluate the effects of the CB2 receptor spe-
cific agonist JWH-133 in APP/PS1 mice, a transgenic
model of AD that mimics the progressive cognitive
deficiency and neurodegenerative process occurring in
this disease [25, 26], not only at the inflammatory and
amyloid level but also at the oxidative stress and tau
kinases levels because of their relevance in AD pro-
gression [1, 2].
MATERIALS AND METHODS
Animals
The experiments were carried out on male
APP/PS1 mice and wild-type littermates aged 3
months (pre-symptomatic) or 6 months (early symp-
tomatic) at the beginning of the study [26]. The
generation of mice expressing the human mutated
forms APPswe and PS1dE9 has been already
described [25]. Animals were maintained under stan-
dard animal housing conditions in a 12-h dark-light
cycle with free access to food and water. Mice
were randomly assigned to treatment groups and the
experiments were conducted under blind experimen-
tal conditions. All animal procedures were conducted
according to ethical guidelines (European Communi-
ties Council Directive 86/609/EEC) and approved by
the local ethical committee (UB-IDIBELL).
RNA extraction and Cnr2 gene expression
quantiﬁcation
Frozen cortical samples obtained from male
APP/PS1 mice and wild-type littermates aged 6
months were used to evaluate the basal expres-
sion of the gene coding for CB2 receptor (Cnr2).
Isolation of total RNA was carried out according
to the manufacturer’s instructions (RNeasy Mini
Kit, Qiagen® GmbH, Hilden, Germany). cDNA was
prepared from 1g total RNA using random hexamers
and SuperScript II RNase H- reverse transcriptase
(Invitrogen, Eugene, OR, USA). For each sample,
SYBR Green real-time quantitative PCR was run
on an ABI Prism® 7900HT Sequence Detection
System (Applied Biosystems Inc, Foster City, CA,
USA) with a melting curve dissociation protocol.
The primer sequences were designed using Primer
Express software and resulted as follows: forward
5’-GGTCGACTCCAACGCTATCTTC-3’ and reverse
5’-GTAGCGGTCAACAGCGGTTAG-3’. Xpnpep1
was used as housekeeping gene for normalization.
Samples were analyzed by the double delta CT
(CT) method.
Pharmacological treatment
The selective CB2 receptor agonist JWH-133
(Ki = 677 nM for CB1 and 3.4 nM for CB2) [27] was
supplied by Tocris Bioscience® (Bristol, UK). JWH-
133 (0.2 mg/kg) was dissolved in 5% ethanol, 5%
Tween, and 90% saline, and this mixture was injected
intraperitoneally (i.p.) in a volume of 10 mL/kg body
weight. Animals treated during the pre-symptomatic
phase received one daily administration for 5 weeks
with JWH-133 or the corresponding vehicle starting
at 3 months of age (n = 6–10 per group). Then, the
behavioral testing was performed when animals were
six months because they are known to exhibit the first
cognitive deficiencies at this age [26]. A second group
of animals were treated during the early symptomatic
phase. These 6-month-old mice were treated once a
day for 5 weeks with JWH-133 or the corresponding
vehicle (n = 6–10 per group). After 10 days of washing
period, animals were subjected to behavioral evalua-
tion. This period was considered enough to ensure that
the animals were void of the direct effect of the com-
pound during the behavioral performance, considering
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the long half-life of cannabinoid compounds in plasma
[28].
Behavioral evaluation of cognitive performance
and sample collection
Two-object recognition test
This paradigm was performed in a V-maze (Pan-
lab, Barcelona, Spain), as previously described [8].
Animals exhibiting memory impairments revealed
decreased object recognition index calculated as the
difference between the time the animals spent explor-
ing either the novel or the familiar object, divided by
the total time spent exploring the two objects.
Active avoidance test
The learning performance of the animals was eval-
uated in a two-way shuttle box apparatus (Panlab),
where mice were trained to avoid an aversive stimulus
associated with the presentation of a conditioned stim-
ulus during 5 consecutive days, as previously described
[8]. The total number of conditioned responses was
recorded.
At the end of the behavioral testing, the animals
were killed and their brains rapidly removed from the
skull and processed for study. One brain hemisphere
was dissected on ice, immediately frozen and stored at
−80◦C until used for the quantification of soluble A
and for cytokine analysis. The other brain hemisphere
was fixed in 4% paraformaldehyde and processed for
immunohistochemistry.
Aβ and synaptophysin immunohistochemistry
Tissue samples were embedded in paraffin, and
coronal sections (4m) were cut with a microtome.
De-waxed sections were incubated with 98% formic
acid (A, 3 min) and then treated with citrate buffer
(20 min) to enhance antigenicity. Then, the endoge-
nous peroxidases were blocked by incubation in 10%
methanol-1% H2O2 solution (15 min). Sections were
blocked with 3% normal horse serum solution and then
incubated at 4◦C overnight with the primary antibody
against A (clone 6F/3D, 1:50, Dako, Glostrup, Den-
mark) or synaptophysin (1:100, Dako). Sections were
subsequently rinsed and incubated with biotinylated
secondary antibody (Dako), followed by EnVision+
system peroxidase (Dako) and finally with the chro-
mogen diaminobenzidine and H2O2. Sections were
lightly counterstained with haematoxylin. After stain-
ing, the sections were dehydrated and cover-slipped for
observation under a Nikon Eclipse E800 microscope
(Nikon Imaging Inc., Tokyo, Japan; Objective: 20×).
The cortical A burden was calculated as the percent-
age of the area of amyloid deposition in plaques with
respect to the total area in 9 representative pictures
taken from the cerebral cortex of each animal, cor-
responding to the main regions where A deposition
is observed in APP/PS1 mice. Three sections of the
hippocampus of each animal were used for quantifica-
tion of the hippocampal A burden. The cortical and
hippocampal A burden of all the APP/PS1 animals
were calculated using the Adobe® Photoshop® CS4
software (Adobe Systems Inc., San Jose, CA, USA),
as previously described [8].
Aβ soluble quantiﬁcation: Enzyme-linked
immunosorbent assay (ELISA)
Fresh-frozen mouse brain cortex was homoge-
nized in 4 volumes (wt:vol) of TBS extraction
buffer [140 mM NaCl, 3 mM KCl, 25 mM Tris (pH
7.4), 5 mM EDTA, and protease inhibitor cocktail
(Roche Molecular Systems, Pleasanton, CA, USA)].
Homogenate was spun 100,000 g × 1 h, and the super-
natant was saved as the soluble fraction for A
quantifications. The A40 and A42 Human ELISA
kits (InvitrogenTM Corporation, Camarillo, CA, USA)
were used to quantify the levels of A40 and A42 pep-
tides in the brain soluble fractions. The quantitative
determination was carried out according to the man-
ufacturer’s instructions, as previously described [8].
A40 and A42 levels were normalized to the total
amount of protein from each individual sample.
Double-labeling immunoﬂuorescence
De-waxed sections were incubated with 98%
formic acid (3 min) for A immunofluorescence
and then treated with citrate buffer (20 min) to
enhance antigenicity, or with a 0.04% borohydride
solution (20 min) for hydroxynonenal (HNE) immuno-
histochemistry. All sections were stained with a
saturated solution of Sudan black B for 30 min
(Merck Millipore, Billerica, MA, USA) to block
lipofuscin autofluorescence, then rinsed in 70%
ethanol and washed in distilled water. After a block-
ade with 10% fetal bovine serum (90 min), the
sections were incubated at 4◦C overnight with com-
binations of primary antibodies against A (clone
6F/3D 1:50, Dako), glial fibrillary acidic protein
(GFAP; 1:250, Dako), Iba1 (1:250, Wako, Rich-
mond, VA, USA), interferon- (IFN, 1:50, Merck
Millipore), phospho-tau (Thr181) (1:250, Merck
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Millipore), phospho-p38 (Thr180/Tr182) (1:100,
Merck Millipore), phospho-stress-activated protein
kinase/Jun-amino-terminal kinase (Thr183/Tyr185)
(phosphor-SAPK/JNK 1:100, Cell Signalling, Beverly,
MA, USA), phospho-glycogen synthase kinase-3
(Ser9) (phospho-GSK3, 1:200, Merck Millipore),
HNE (1:1000, Merck Millipore), superoxide dismutase
1 (SOD1, 1:1,000, Novocastra-Leica Biosystems, Nus-
sloch, Germany), SOD2 (1:500, Stressgen-Gentaur,
Brussels, Belgium), proliferating cell nuclear anti-
gen (PCNA, 1:500, Oncogene Science, Cambridge,
MA, USA), and voltage-dependent anion channel
(VDAC, 1:100, Calbiochem, Denmark). After wash-
ing, the sections were incubated with Alexa488 or
Alexa546 fluorescence secondary antibodies against
the corresponding host species (1:400, Molecular
Probes, Eugene, OR, USA). Then, they were washed
and mounted in Immuno-Fluore Mounting medium
(ICN Biomedicals, Solon, OH, USA), sealed, dried
overnight and examined with an Nikon Eclipse E800
microscope (Objective: 40×; Red filter: Excitation
540-25 nm- Emission 605-55 nm; Green filter: Exci-
tation 480-30 nm- Emission 605-55 nm). The specific
GFAP, Iba1, phospho-tau, phospho-p38, phospho-
SAPK/JNK, phospho-GSK3, HNE, SOD1 and SOD
2 immunostaining density was calculated in reference
to the A plaque area in 5 representative pictures taken
from the cortex of each animal (n = 5 per group) using
the Adobe® Photoshop® CS4 software. In the case of
IFN, specific density was in reference to the GFAP
immunostained area.
Cytokine quantiﬁcation
The murine IL1, IL-6, IL10, and TNF Mini
ELISA Development kits (PeprotechTM, Rocky Hill,
NJ, USA) were used to quantify the levels of these
cytokines in cortical brain homogenates (RIPA buffer).
The quantitative determination was carried out accord-
ing to the manufacturer’s instructions. Cytokine levels
were normalized to the total amount of protein from
each individual sample and expressed with respect to
the control group.
Statistical analyses
The sample size for experimentation was com-
puted using the Power and Precision software (Biostat,
Englewood, NJ, USA), assuming a power of 95% and
no missing data. Data were analyzed with two-way
ANOVA with genotype and treatment as between fac-
tors, followed by Tukey’s post hoc when required. A
burden and immunofluorescence quantifications were
analyzed with Student’s t-test. In all the experiments,
the significance level was set at p < 0.05.
RESULTS
CB2 gene expression appears to be upregulated in
AβPP/PS1 mice
In cortical homogenates of non-treated APP/PS1
mice aging 6 months, we observed a clear tendency
to upregulate the CB2 gene expression levels when
compared to wild-type littermates (WT: 1.00 ± 0.09;
APP/PS1: 1.39 ± 0.19; n = 14–15; p = 0.071). This
result is in line with the reported CB2 receptor upreg-
ulation in AD [15] and supports the hypothesis of this
receptor as a potential target against AD.
Cognitive improvement of AβPP/PS1 mice treated
with JWH-133 during the pre-symptomatic stage
APP/PS1 mice treated for 5 weeks with JWH-
133 (0.2 mg/kg) during the pre-symptomatic stage
(mice aged 3 months) did not exhibit the memory
impairment revealed by the two-object recognition
test in vehicle-treated APP/PS1 mice at the age
of 6 months when compared to wild-type animals
(p < 0.001) (Fig. 1A). Thus, JWH-133 significantly
increased the recognition index of APP/PS1 mice
when compared to vehicle-treated animals (p < 0.01).
Similarly, APP/PS1 mice treated with JWH-133 dur-
ing the pre-symptomatic stage significantly improved
their learning performance when compared to vehicle-
treated APP/PS1 mice in the active avoidance test
at the age of 6 months (Fig. 1C). For statistic details
see Supplementary Table 1 (available here: http://
dx.doi.org/10.3233/JAD-130137).
JWH-133 treatment during early stages of the
symptomatic phase partially reversed the cognitive
deﬁcits in AβPP/PS1 mice
Daily stimulation of CB2 receptors for 5 weeks
at the early stages of the symptomatic stage (6
months) reversed the memory impairment exhibited
by vehicle-treated APP/PS1 mice on the two-object
recognition test when compared to wild-type animals
(p < 0.01) (Fig. 1B). Accordingly, JWH-133 signifi-
cantly increased the recognition index of APP/PS1
mice when compared to vehicle-treated littermates
(p < 0.001).
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Fig. 1. Cognitive improvement of APP/PS1 mice chronically treated with JWH-133 during the pre-symptomatic stage (3 months, left panels)
and during the beginning of the symptomatic stage (6 months, right panels). A, B) Memory performance in the V-maze. JWH-133 chronic
administration during the pre-symptomatic (A) or symptomatic (B) stages reverses APP/PS1 memory deficiency when compared to vehicle-
treated animals. C, D) Learning impairment exhibited by APP/PS1 mice in the active avoidance test during the five consecutive days of
training is not evidenced after chronic JWH-133 administration during the pre-symptomatic stage (C). In contrast, JWH-133 treatment during
the symptomatic stage is not able to modify learning deficiencies in APP/PS1 mice (D). Data are expressed as the mean values ± SEM of
conditioned responses (n = 6–10 per group). p < 0.05, p < 0.01, p < 0.001, genotype effect; p < 0.05, p < 0.01, p < 0.001,
treatment effect.
However, JWH-133 did not significantly rescue
APP/PS1 learning impairment in the active avoidance
paradigm when administered at the beginning of the
symptomatic stage (Fig. 1D). These results reveal that
the efficacy of CB2 receptor agonists is greater when
the treatment is started at an early pre-symptomatic
stage of the disease. For statistical details, see Supple-
mentary Table 1.
JWH-133 treatment did not modify the cortical
and hippocampal Aβ burden, the cortical soluble
fraction, or synaptic markers in AβPP/PS1 mice
Chronic treatment with JWH-133 in APP/PS1
mice beginning at the age of either 3 or 6 months did
not significantly modify the A burden in the cortex or
the hippocampus, a region where A deposition in our
murine AD model starts later and is less intense than
in the cortex [26] (Fig. 2A, C). Similarly, no differ-
ence was observed in the A40 or A42 protein levels
of APP/PS1 cortical soluble fraction in either of the
two settings (Fig. 2B). Moreover, no significant JWH-
133 effect was observed in the cortical or hippocampal
expression of synaptophysin, considered as a marker of
synapses, and VDAC around the A deposition, which
indicates the extension of polymorphous inclusions in
dystrophic neurites (Supplementary Figure 1).
Modulation of the gliosis associated with Aβ
deposition and cytokine expression following
JWH-133 treatment at the early symptomatic stage
in AβPP/PS1 mice
Because of the potential relevance for therapeutic
intervention, the next studies were carried out with the
cortical samples obtained from the APP/PS1 mice
chronically treated during the early symptomatic stage
(6 months of age).
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Fig. 2. A) Cortical (Cx) or hippocampal (HC) A burden in APP/PS1 mice is not modified by chronic JWH-133 treatment during the pre-
symptomatic stage or during the early symptomatic stage. Compared to cortex, the A burden in hippocampus of APP/PS1 mice is relatively
low. B) Neither A40 nor A42 cortical soluble fractions are modified in APP/PS1 mice chronically treated with JWH-133 during the pre-
symptomatic stage or during the early symptomatic stage. Data are expressed as the mean values ± SEM (n = 6 per group). C) Representative
images of the A immunoreactivity in cortical coronal sections of APP/PS1 mice treated during the pre-symptomatic stage (upper panels) and
during the early symptomatic stage (lower panel). Scale bar represents 100m.
Double-immunofluorescence revealed that CB2
receptor stimulation did not produce any significant
effect on the number of astrocytes around A plaques
(Fig. 3A to C). However, the number of microglial
cells associated with A plaques was significantly
reduced by JWH-133 (p < 0.001) in comparison to
vehicle-treated APP/PS1 animals (Fig. 3D to F).
Reduction in microglial response was associated with
a decrease in the expression levels of several pro-
inflammatory cytokines. Thus, a reduction in the
pro-inflammatory cytokine IFN was revealed by
densitometric quantification in astrocytes surrounding
A plaques in JWH-133-treated APP/PS1 animals
(Fig. 3G to K, p < 0.001). Moreover, the ELISA
results demonstrated that JWH-133 was also able
to mitigate (p < 0.05 when compared to vehicle in
all the cases) the increase in the pro-inflammatory
cytokine IL-1 (p < 0.001), IL-6 (p < 0.001), and
TNF (p < 0.05) levels exhibited by APP/PS1 with
respect to control wild-type littermates (Fig. 3L to N).
For statistical details, see Supplementary Table 1. Sim-
ilar JWH-133-induced reduction in the levels of the
anti-inflammatory cytokine IL-10 (p < 0.05) was also
observed with respect to vehicle-treated APP/PS1
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Fig. 3. JWH-133 reduces microglial and pro-inflammatory responses in APP/PS1 mice during the early symptomatic stage. A–C) Double-
immunofluorescence staining of GFAP (red) and A (green) reveals no effect of JWH-133 on astroglial reactivity around plaques. D–F) In
contrast, Iba1 staining (red) reveals a reduction of microglia surrounding A plaques (green) after treatment. Scale bar represent 100m. The
evaluation of several cytokines confirms the anti-inflammatory effect of the CB2 agonist in APP/PS1. Densitometric quantification of the levels
of IFN (green) expressed by astrocytes (red) revealed a reduction in JWH-133-treated APP/PS1 mice (G–K) (n = 5 per group). Scale bar
represents 50m. Similarly, the CB2 agonist was able to mitigate the increase of pro-inflammatory cytokines IL-1 (L), IL-6 (M), and TNF
(N), and to decrease the levels of the anti-inflammatory cytokine IL-10 (O) in the cortex of APP/PS1, as measured by ELISA (n = 6 per group).
However, JWH-133 increases the levels of IL-6 and IL-10 in wild mice. Data are expressed as the mean values ± SEM. p < 0.05, p < 0.01
p < 0.001 genotype effect; p < 0.05, p < 0.01, p < 0.001 treatment effect.
animals (Fig. 3O), which exhibited increased IL-10
levels when compared to vehicle wild-type animals
(p < 0.05).
Interestingly, chronic administration of JWH-133
induced an increase in the levels of IL-6 (p < 0.01)
and IL-10 (p < 0.001) (Fig. 3), and increased
the number of microglial cells observed in the
cortex of wild-type animals (See Supplementary Fig-
ure 2). Increased numbers of microglial cells were not
associated with higher levels of proliferating (PCNA
positive) Iba1-immunoreactive cells (Supplementary
Figure 3).
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Fig. 4. Double-immunofluorescence staining of A (green) and phospho-tau (Thr181) and related kinases (red). A–C) JWH-133 reduces the
amount of tau phosphorylated at the Thr181 in the area surrounding A plaques in APP/PS1 mice treated during the early symptomatic stage.
D–F) A reduction in the activity of p38 kinase (p38-P) is observed after chronic treatment with the CB2 agonist during the early symptomatic
stage. G–I) A similar decrease in the activity of the SAPK/JNK (SAPK/JNK-P) is observed in the vicinity of A plaques in JWH-133-treated
animals. J–L) The activity of GSK3 is also reduced around A plaques in treated animals, as indicated by the increased immunoreactivity of
the inactivated form of GSK3 phosphorylated at Ser9. Scale bars represent 75m. Data are expressed as the mean values ± SEM (n = 5 per
group). p < 0.05, p < 0.01 compared to vehicle-treated animals.
Decreased tau phosphorylation and selected tau
kinase activity in the vicinity of Aβ plaques by
JWH-133 in AβPP/PS1 mice
Even although our animal model of AD presents
with only small amounts of phospho-tau in dystrophic
neurites, which do not produce neurofibrillary tangles
at any age in APP/PS1 mice and are never on a par
with those seen in AD brains [26], we decided to eval-
uate the levels of phospho-tau because they are known
to have a detrimental effect on soluble A and to con-
tribute to the neurodegenerative process [29].
Double-immunofluorescence and quantitative den-
sitometry showed significant reduction (p < 0.01) of
tau phosphorylated at the Thr181 site in neuritic pro-
cesses surrounding A plaques in JWH-133-treated
APP/PS1 mice (Fig. 4A to C). This was associated
with the decreased activity of three well-known tau
kinases, as revealed by the local reduced expression
of active stress-induced kinases p38 (phosphorylated
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Fig. 5. A–C) Decreased staining of HNE (red) in the area surrounding A plaques (green) in APP/PS1 mice treated with JWH-133 during the
early symptomatic stage. This is accompanied by an increase in the expression of SOD1 (D–F) and SOD2 (G–I) (red) around A plaques (green)
(D–I). Scale bars represent 75m. Data are expressed as the mean values ± SEM (n = 5 per group). p < 0.05 compared to vehicle-treated
animals.
at Thr180/Tr182) (Fig. 4D to F, p < 0.01) and
SAPK/JNK (phosphorylated at Thr183/Tyr185)
(Fig. 4G to I, p < 0.05), and the increased expres-
sion of the inactive form of GSK3 (GSK3
phosphorylated at Ser9) (Fig. 4J to L, p < 0.05) in
JWH-133-treated APP/PS1 mice when compared to
transgenic animals treated with vehicle.
Reduction of oxidative stress damage by JWH-133
in AβPP/PS1 mice
Considering the reduction induced by JWH-133 in
the activity of the SAPK/JNK and p38 kinases and the
well-documented induction of both enzymes by the
oxidative stress [30, 31], we evaluated if the CB2 ago-
nist could also reduce the consequences of oxidative
stress occurring in APP/PS1 mice. With this pur-
pose, we quantified by densitometry the HNE adducts
immunostaining in cortical areas surrounding the A
deposition in animals. HNE immunostaining was sig-
nificantly reduced (p < 0.05) in the vicinity of the A
plaque area in APP/PS1 animals chronically treated
with JWH-133 (Fig. 5A to C). This was accompanied
by increased SOD1 (Fig. 5D to F, p < 0.05) and SOD2
(Fig. 5G to I, p = 0.06) immunoreactivity around A
plaques.
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DISCUSSION
The present observations show that the admin-
istration of the specific CB2 agonist JWH-133
prevented cognitive impairment in APP/PS1 trans-
genic mice when the administration was started at
pre-symptomatic stages (3 months), and reversed
the long-term recognition memory decline but did
not improve the aversive avoidance learning capac-
ity when the treatment was started at symptomatic
stages (6 months). This positive cognitive effect was
associated with reduced inflammation manifested as
decreased microglial reaction and reduced expression
of cytokines IL-1, IL-6, TNF, and IFN. These
observations are in agreement with those already
reported in Tg2576 mice bearing the APP Swedish
mutation and in animals inoculated with A [18–21,
32, 33], and can be related with the direct role of CB2
receptors in inhibiting the microglia-mediated neu-
rotoxicity [18]. The described upregulation of CB2
receptors in AD brains [15], which is also apparent in
APP/PS1 mice, is suggested to account for an attempt
to reduce the ongoing neurodegenerative process.
However, JWH-133 was not able to reduce A
plaques and soluble A in the cortex of APP/PS1
mice. We also confirmed that the CB2 agonist failed
to modify the A burden in the hippocampus. In spite
of the low affectation exhibited by APP/PS1 mice in
the hippocampus compared to cortex [26], this brain
area was also evaluated for the A burden because
of its relevant role in learning and memory. The lack
of JWH-133 effect on A processing in our model
of AD is in contrast with two previous studies show-
ing that activation of CB2 receptors stimulated A
removal in vitro by human macrophages [22] and in
Tg2576 mice by favoring A transport through the
choroid plexus [20]. However, we should take into
consideration that the experimental conditions were
different, as the demonstration of A removal in vitro
was carried out using frozen human tissue and cul-
tured macrophages exposed to a determinate amount
of A fibrils [22] and the in vivo experiments were per-
formed in a different animal model exposed to a more
prolonged treatment than the described in the present
study.
The JWH-133 treatment did not affect the synap-
tophysin density in cortex or hippocampus and the
content of VDAC-positive polymorphous inclusions in
dystrophic neurites of A plaques. Thus, we have no
morphological evidence about a neuroprotective effect
of JWH-133 in APP/PS1 mice. However, we consider
that the cognitive improvement is evidence by itself
of the preserved neuronal functionality in JWH-133-
treated animals.
In addition to the effects on inflammatory responses,
the present results show for the first time other benefi-
cial effects induced by the chronic stimulation of CB2
receptors. Thus, APP/PS1 mice treated with JWH-
133 exhibited reduced levels of tau hyperphosphoryla-
tion at Thr181 in dystrophic neurites surrounding A
plaques. Although the levels of phospho-tau are scarce
when compared to AD brains and do not produce neu-
rofibrillary tangles at any age in APP/PS1 mice, they
are a characteristic feature of our animal model of AD
and are supposed to be a detrimental effect of soluble
A forms [26, 29]. Then, the JWH-133-induced reduc-
tion of tau hyperphosphorylation at Thr181 reveals
a protection against deleterious effects of A and a
preservation of tau functionality by CB2 stimulation.
Previous studies reported the ability of non-selective
cannabinoids to modulate tau phosphorylation but
failed to demonstrate a specific role for CB2 recep-
tors [23, 24]. Reduced tau hyperphosphorylation may
be explained by decreased activity of GSK3, p38,and
SAPK/JNK kinases in the vicinity of A plaques [34],
as observed following chronic JWH-133 administra-
tion in APP/PS1 mice. To our knowledge, this is the
first report indicating a specific role of CB2 recep-
tors in the modulation of GSK3. A previous study
revealed the normalization of the phospho-GSK3 lev-
els in other AD model by mixed CB1/CB2 agonist
prolonged administration, but failed to demonstrate
a positive effect by the specific CB2 agonist JWH-
133 [20]. This apparent discrepancy with our results
could be due to the different experimental approach,
since the previous study assessed the levels of the inac-
tive form of GSK3 in cortical homogenates, rather
than in the specific brain areas directly affected by
A deposition. Increased GSK3 activity has been
related to the memory impairment and the inflam-
matory responses mediated by microglia in AD [35].
Thus, the JWH-133-induced reduction in the GSK3
activity could account for the reduction of the AD-like
phenotype in APP/PS1 mice beyond the effect on tau
phosphorylation. Regarding the other two tau kinases
evaluated, a previous study performed on human coro-
nary smooth muscle cell culture revealed that CB2
agonists were able to attenuate the activation of p38
and SAPK/JNK induced by the pro-inflammatory
cytokine TNF [36]. Therefore, it seems reasonable
to assume that the reduction in the levels of TNF in
our JWH-133-treated APP/PS1 mice may provide an
explanation, at least in part, for the decreased activity of
p38 and SAPK/JNK in our paradigm. However, other
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mechanisms may participate in the activation of these
two kinases, such as A-mediated oxidative stress [30,
31, 37]. In this line, reduced HNE immunoreactivity
and enhanced SOD1 and SOD2 immunoreactivity in
the vicinity of plaques in JWH-133-treated compared
with vehicle-treated APP/PS1 mice, indicates that
CB2 receptors have the capacity to modulate oxida-
tive stress responses and oxidative stress damage. The
present observations, although novel in AD models,
are in accordance with previous studies suggesting a
role for CB2 receptors as antioxidant mediators in other
neurodegenerative settings [38–40].
Collateral observations also deserve a comment.
Surprisingly, we observed that administration of
JWH-133 to wild mice induced an increase in the
number of microglial cells and enhanced expression
of IL-6 and IL-10. The reasons for this increase
are not clear, as no increase in the proliferation of
microglia can be proven. However, we cannot rule
the possibility that CB2 receptor activation enhances
microglial migration as shown in other paradigms
[41]. Nevertheless, the clinical implications appear to
be limited, as the behavior of these animals did not
manifest any apparent deleterious effect.
In summary, our present results reveal that the CB2
cannabinoid agonist JWH-133 is able to ameliorate
cognitive symptoms in an experimental model of AD
by reducing inflammation, stress oxidative responses
to A, GSK3 activity, and tau hyperphosphoryla-
tion around A plaques. These findings reinforce the
hypothesis that the activation of CB2 cannabinoid
receptor, which is devoid of psychoactive side effects,
could be considered a potential target for the develop-
ment of novel therapeutic strategies against AD.
SUPPLEMENTARY MATERIAL
Supplementary material is available here: http://
dx.doi.org/10.3233/JAD-130137
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